NASDAQ: ITRM
Iterum Therapeutics PLC Stock Ownership - Who owns Iterum Therapeutics?

Insider buying vs selling

Have Iterum Therapeutics PLC insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Michael W. DunneDirector2025-11-186,000$0.37
$2.19kBuy
Michael W. DunneDirector2025-08-0815,000$0.72
$10.86kBuy

1 of 1

ITRM insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when ITRM insiders and whales buy or sell their stock.

ITRM Shareholders

What type of owners hold Iterum Therapeutics PLC stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Ra Capital Management LP22.07%11,651,597$3.58MInsider
Brenton Karl Ahrens3.28%1,733,580$532.21kInsider
Canaan X LP3.28%1,733,170$532.08kInsider
James Healy3.28%1,732,668$531.93kInsider
Patrick J. Heron2.93%1,547,322$475.03kInsider
Vijay K. Lathi2.76%1,456,303$447.09kInsider
Sofinnova Venture Partners IX LP2.32%1,226,514$376.54kInsider
Shahzad Malik1.64%868,161$266.53kInsider
Squarepoint Ops LLC0.84%443,972$136.30kInstitution
Ronald Hunt0.68%359,366$110.33kInsider

1 of 3

ITRM vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
ITRM2.52%43.21%Net BuyingNet Buying
CASI3.18%96.82%
LEXX6.90%3.28%Net Buying
TRAW4.83%95.17%Net Buying
LIMN0.97%85.86%

Iterum Therapeutics Stock Ownership FAQ

Who owns Iterum Therapeutics?

Iterum Therapeutics (NASDAQ: ITRM) is owned by 2.52% institutional shareholders, 43.21% Iterum Therapeutics insiders, and 54.27% retail investors. Ra Capital Management LP is the largest individual Iterum Therapeutics shareholder, owning 11.65M shares representing 22.07% of the company. Ra Capital Management LP's Iterum Therapeutics shares are currently valued at $3.48M.

If you're new to stock investing, here's how to buy Iterum Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.